What is the current stock price of Invivyd, Inc. (IVVD)?

As of the latest market data, Invivyd, Inc. (IVVD) is trading at $1.13. The stock has seen a gain of 2.73% today.

Does Invivyd, Inc. (IVVD) pay a dividend?

Based on current data, Invivyd, Inc. does not have a confirmed active dividend policy.

What is the market cap of Invivyd, Inc.?

The current market capitalization of Invivyd, Inc. (IVVD) is approximately unavailable.

IVVD

Invivyd, Inc.·Healthcare

1.13

2.727%(+0.03)

Close Price

1.29

14.159%(+0.16)

After Hours

Last Updated: — ET

52W L: $0.4852W H: $3.07

IVVD NEWS

globenewswire.com

18h ago

Invivyd to Participate in Upcoming Investor Events

NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June:

globenewswire.com

18h ago

Invivyd to Participate in Upcoming Investor Events

NEW HAVEN, Conn. , May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that it will participate in upcoming investor events in June: 2026 Jefferies Global Healthcare Conference in New YorkFireside Chat Date and Time: Wednesday, June 3, 2026 4:55 p.

seekingalpha.com

May 14

Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript

marketbeat.com

May 14

Invivyd Q1 Earnings Call Highlights

Invivyd NASDAQ: IVVD said its first quarter of 2026 was marked by continued progress in its pivotal COVID-19 antibody program, year-over-year growth for PEMGARDA and elevated clinical spending tied to its VYD2311 development efforts.

zacks.com

May 14

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.14 per share a year ago.

globenewswire.com

May 14

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 million Invivyd in vitro data showed continued neutralizing activity of pemivibart and VYD2311 against SARS-CoV-2 variant BA.3.2.2 (“Cicada”), confirming anticipated activity DECLARATION trial Independent Data Monitoring Committee (IDMC) ad hoc review of unblinded VYD2311 safety data resulted in IDMC recommendation for reduction of post-dose monitoring time from two hours to thirty minutes Operating expense increase quarter-over-quarter primarily attributable to DECLARATION pivotal program costs for VYD2311 for which top-line data is anticipated in Q3 2026 Strong balance sheet with Q1 2026 ending cash and cash equivalents of $184.2 million; additional ~$20 million in gross proceeds from usage of at-the-market (ATM) offering facility in April 2026 Invivyd to host conference call today at 8:30AM ET NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced financial results for the first quarter ended March 31, 2026, and recent business highlights.

Company Profile

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2021-08-06

Beta

0.71

Websiteadagiotx.com↗